Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Kona SUV: The Courageous Minimized That is Catching Hearts Around the world - 22024 Moving Styles for Kitchen Redesigns
- 3The most effective method to Pick the Right Volvo XC40 Trim for Your Way of life
- 4Italy now recognizes the crime of femicide and punishes it with life in prison
- 5Tasting America: An Excursion Through Darling Cheap Food Brands
- Damaged launch pad: How long before Russia can send astronauts to the ISS again?
- Mom finds out she has cancer after noticing something was off while breastfeeding
- Tragedy in Minnesota, vaccine news, Snoop's game call: Week in review
- Where should we send a real 'Hail Mary' spacecraft? A new study has the answers
- Famous Restroom Beautifying Styles For 2024
- Terminal cancer diagnosis announced by JFK's granddaughter
- The Iran war’s energy security legacy
- The Beginning Of The End For Fossil Fuels Can Start In Colombia
- Exhaustive Experiences into Prudent Senior Living in the UK
